Unicycive Therapeutics (UNCY) Projected to Post Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) will likely be issuing its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $0.5170 million for the quarter.

Unicycive Therapeutics Trading Down 3.6%

Shares of UNCY stock opened at $6.39 on Friday. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00. The firm’s 50 day moving average is $6.66 and its 200-day moving average is $5.73. The firm has a market capitalization of $137.32 million, a price-to-earnings ratio of -1.62 and a beta of 1.82.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics during the 2nd quarter valued at $55,000. Vanguard Group Inc. raised its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $512,000. Finally, Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $182,000. 40.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UNCY has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Guggenheim reissued a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Westpark Capital assumed coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.